Research Article Open Access
Normocalcemic Primary Hyperparathyroidism
Mamta Ojha1*, G. Mathew Hebdon2, Saleh Aldasouqi2, Ved Gossain2
1Faculty of General Internal Medicine, Michigan State University, East Lansing, MI 48824, USA
2Department of Endocrinology, Michigan State University, East Lansing, MI 48824, USA
*Corresponding author: Mamta Ojha, Faculty of General Internal Medicine, Michigan State University, East Lansing, MI 48824, USA, Tel: +309-363-0997; E-mail: @
Received: July 13, 2016; Accepted: September 01, 2016; Published: September 07, 2016
Citation: Ojha M, Hebdon GM, Aldasouqi S, Gossain V (2016) Normocalcemic Primary Hyperparathyroidism 3(3): 1-4.
The prevalence and the natural history of Normocalcemic Primary Hyperparathyroidism (NCHPT) are not well known. Therefore the aim of this retrospective study was to determine the prevalence and natural history of (NCHPT).

We reviewed the electronic medical records of patients with normal serum calcium level (8-10.5 mg/dl) and elevated serum Parathyroid Hormone (PTH) level (>72 pg/ ml) over a period of 10 years (2003 to 2013), mean period of 4.6 years, ranging 1-8 years at Michigan State University outpatient clinics. During this time, no patient was sent for parathyroidectomy but simply followed. We identified 332 patients to have primary hyperparathyroidism out of which 50 were normocalcemic. Out of these twenty-seven (54%) patients were found to have vitamin D deficiency (25 Hydroxy vitamin D level< 30ng/ml), and 2 patients taking hydrocholorothiazide were excluded. Thus the prevalence of NCPHPT is 21 /332 (6.3%). Bone mineral density had been determined in 13 patients. 6/13 (46.1%) showed osteoporosis, 5/13 (38.46%) had osteopenia and 2/13 were normal. Two patients 2/21 (9.5%) had history of recurrent fractures, and 6 (28.5%) had recurrent kidney stones. Among those with Vitamin D deficiency, PTH level returned to normal only in 7 patients over a period of 3 months to 4 years after the correction of the deficiency. In 20 patients, PTH remained elevated throughout the follow up ranging from 2 months to 7 years.

This retrospective analysis shows that among all patients with hyperparathyroidism about 6.3% may have NCHPT. Our data also shows that NCPHPT is not a benign entity and may be associated with increased risk of osteopenia, osteoporosis and kidney stones.
Normocalcemic Primary Hyperparathyroidism (NC-PHPT) is a clinical entity characterized by normal serum calcium and persistently elevated parathyroid (PTH) levels. These patients have no obvious causes for secondary hyperparathyroidism such as vitamin D deficiency and renal insufficiency [1,2-16,17]. None of the patients had clear evidence of gastrointestinal disease. Although the entity NC-PHPT is now well recognized it's natural history and the course is not well known. Therefore our aim of the study was to evaluate the prevalence and the natural course of NCPHPT. To the best of our knowledge, the term normocalcemic primary hyperparathyroidism was first used by Wills, et. al [18]. Since then, several studies have described the various aspects of this entity [1,2-16,17].
Study Design and Method
We retrospectively evaluated the medical records of patients with normal serum calcium (8-10.5 mg/ dl) and elevated serum Parathyroid Hormone (PTH) level (> 72 pg/ ml) over a period of 10 years (2003-2013) at Michigan State University outpatient clinics. We excluded the patients with chronic liver disease, kidney disease (GFR < 90), vitamin D deficiency and subjects taking Lithium or Hydrochlorothiazide to exclude causes of secondary hyperparathyroidism. Subjects with previous parathyroid surgery were also excluded.
We identified 332 patients to have primary hyperparathyroidism out of which 50 were normocalcemic. Out of these, twenty seven (54%) patients were found to have vitamin D deficiency (25 hydroxy vitamin D level < 30 ng/ ml) and 2 patients were taking HCTZ. These were excluded from further analysis. We therefore had 21 patients who were found to have NCHPT. Hence, the prevalence of NCPHPT appears to be 21/332 (6.32%). The baseline characteristics of these 21 patients are shown in Table 1. Out of those 21 patients, 7 had serum calcium > 10 occasionally. However, the level would rise and fall. 3 (~15%) of them eventually had serum calcium > 10.5. 1 of those 3 subsequently had normal serum calcium levels whereas 2 of them continued to have serum calcium >10.5 for the next 3 years until we could obtain the data. Although the
Table 1: Baseline characteristics of patients with NCPHT.

Age (years)

Mean-60.9 ± 13.2

Gender M/ F


Serum Albumin ( gm/ dl)

Mean = 4.2 ± 0.3               Range = 3.5-4.8

Serum Calcium (mg/ dl)

Mean = 9.4 ± 1.0               Range = 8.08-11.12

Serum PTH (pg/ ml)

Mean = 118.3 ± 51.3         Range = 74.5-388.2

Vitamin D (ng/ ml)

Mean = 42.1 ± 16.1           Range = 30.9-78.6

initial total serum calcium level was normal in all patients, 2 (7.4%) had elevated ionized calcium, and 5 (23.8%) had normal ionized calcium. Ionized calcium was not measured in 14 (66.6%) patients. Serum albumin was normal in all. Hence, no additional albumin related adjustments were made. Bone mineral density had been determined in 13 patients. 6/13 (46.1%) showed osteoporosis, 5/13 (13.4 %) had osteopenia and 2/13 (15.3%) were normal. Two patients (9.5%) had history of recurrent fractures, and 6 (28.5%) had recurrent kidney stones. Out of 6 patients with recurrent stones only one had BMD checked which showed osteopenia.
In this retrospective study we found the prevalence of NCPHPT to be approximately 6.3%. In prospectively studied patients the prevalence has ranged from 0.5 to 16.7% [9-11]. Garcia et al reported a prevalence of 6% in 100 postmenopausal women, which is very similar to the prevalence in our study [11].

In our study, vitamin D deficiency was the most common cause of elevated PTH level in the presence of normal serum calcium. Vitamin D deficiency is a well-known cause of secondary hyperparathyroidism [1]. An inverse relationship exists between 25-hydroxivitamin D and PTH [19]. When vitamin D decreases below the normal range, the parathyroid gland responds with increased synthesis and secretion of PTH. The level of 25-hydroxivitamin D at which this occurs is somewhere between 20 and 30 ng/ mL [19]. A recent informal consensus of investigators active in the field settled on a value of 30 ng/ ml [20]. However the mechanism by which the vitamin D deficiency increases PTH levels is not clear, at least it does not seem to be mediated through serum calcium levels because the serum calcium levels are normal and yet the PTH levels are elevated. In a very large study based on laboratory collected specimens, Valcour et al observed that 40% and 51% subjects with 25 (OH) levels below 20 and 10 ng/mL respectively had biochemical hyperparathyroidism with serum PTH level greater than 65 pg/ ml, the upper level of normal in their study [21]. However there was no threshold above which increasing levels of 25 (OH) vitamin D levels further suppressed PTH levels [21]. Unfortunately serum calcium levels were not available. Therefore it is difficult to evaluate whether the PTH response was directly related to the vitamin D levels or mediated through serum calcium levels. In another Italian study, serum PTH levels were significantly correlated with age, 25 (OH) D and calcium intake [22].

In patients where vitamin D deficiency is the cause of elevated PTH level, it is expected that PTH levels will fall into the normal range after vitamin D deficiency is corrected. However, that does not appear to be the case in all patients. In a study of Asian patients with vitamin D deficiency, PTH normalized only in 45-55% subjects [23]. In another study of secondary hyperparathyroidism in patients with osteoporosis, Yendt, et. al. [24] observed that in 1/3 of patients the standard treatment of vitamin D deficiency (1,000 unit of vitamin D3 daily or 50,000 IU vitamin D2 once weekly) failed to correct secondary hyperparathyroidism. In our study among those with vitamin D deficiency, PTH level returned to normal only in 7 patients over a period of 3 months to 4 years after the correction of the deficiency. In two patients, PTH levels gradually declined but did not reach normal levels despite having normal vitamin D level, for a period of 3 and 7 years. In 18 patients, PTH remained elevated throughout the follow up ranging from 2 months to 5 years.

A strict definition of NCPHPT requires that the serum calcium be in the normal range with an elevated PTH level. This for practical clinical purposes means that the albumin corrected serum calcium is in the normal range. It has been suggested that both total and serum ionized calcium should be in the normal range [12]. However; reliability of ionized calcium in clinical laboratories may be questionable. While the measurement of total calcium, albumin and total protein is available in standard laboratories, measurement of ionized calcium remains more difficult and is generally performed only in reference laboratories [25]. Several factors may affect the measurement of ionized calcium including patient posture, tourniquet, pH of the sample, and the time it takes to process the sample. Samples must be drawn anaerobically, avoiding heparin contamination, transported on ice, and must be processed within hours. These conditions, if not strictly adhered to, make the determination of ionized calcium somewhat unreliable in routine clinical laboratories [25,26].

Despite these reservations in several studies reported as NCPHPT the ionized calcium level was not reported [8,11,14,15].

The spectrum of presentation of primary hyperparathyroidism has changed over the years from symptomatic to asymptomatic after routine biochemical measurement of serum calcium became available in 1970's [27]. In 1988, Rao, et. al, [28] suggested that primary hyperparathyroidism may be a biphasic disease. During the first phase, PTH levels are elevated, but serum calcium is normal. Until recently, the first phase was subclinical because PTH levels were rarely measured when the serum calcium was normal. The second phase is the one that has traditionally been recognized because of the development of hypercalcemia.

Thus, normocalcemic PHPT may represent an early or mild form of hypercalcemic PHPT, detected when the only biochemical abnormality is an elevated PTH concentration (14). Maruani, et. al, [16] suggested that normocalcemic primary hyperparathyroidism may be due to target organ resistance to the actions of PTH. In their studies, normocalcemic subjects demonstrated inadequate suppression of PTH in response to an oral calcium load. Fasting bone turnover markers and net skeletal calcium release were also lower in the normocalcemic group compared to the hypercalcemic group.

The natural history and clinical presentation of NCPHPT is not well described. Many patients come from referral centers where PTH levels may have been obtained for other reasons, such as evaluation of osteopenia/osteoporosis or renal stones. In the cohort evaluated by Cusano, et. al, [1], at the time of diagnosis, 57% had osteoporosis by bone mineral density. 11% had fragility fractures, and 14% had nephrolithiasis. Other studies have described the prevalence of osteoporosis ranging from 46-73%, fragility fractures 11%, and renal stones from 9-14% [7,14]. In a large study where 187 patients with NCPHPT were followed, Siporva, et. al, [3] reported that another endocrine disease was present in 76% of subjects. Reduced bone density was present in 42%, arterial hypertension in 47%, ischemic heart disease in 40%, and a history of nephrolithiasis in 4%. Diabetes mellitus was diagnosed in 13% patients. It was reported that the thyroid diseases, mainly nodular goiter, and primary hypothyroidism was the most common endocrine disorder noted in this group, but the exact frequency was not described [3]. In our study, we noted that 46.1% had osteoporosis and 13.4% had osteopenia. 9.5% had history of recurrent fractures, 28.5% had recurrent kidney stones.

Although the treatment guidelines for hypercalcemic primary hyperparathyroidism are well described [29], there are no definite therapeutic recommendations for the treatment of NCPHPT. Most of the patients are asymptomatic and a careful follow up is all that may be needed. We agree with Cusano, et. al, [1] that annual serum calcium, PTH and BMD measurements seem reasonable. If the disease progresses to the hypercalcemic phase then the guidelines of the 4th International Workshop for Surgical Management of Asymptomatic Primary Hyperparathyroidism should be followed [29].
Study Limitations
This being a retrospective study, all causes of secondary hyperparathyroidism such as age, BMI, waist circumference, calcium intake, subclinical gastrointestinal disorders, hypercalciuria, hyperaciduria etc could not be taken into account. We acknowledge that the lack of measurement of ionized calcium is an important limitation as total serum calcium level can be unreliable when there is a major shift in serum protein or PH [30]. However, we also want to emphasize that all of our patients had normal serum albumin and normal renal function. Moreover, there was no clear evidence of acid base imbalance based on the lab tests available.
This retrospective analysis shows that among all patients with hyperparathyroidism about 6% may have NCHPT. Vitamin D deficiency is frequently associated with elevated PTH, but normal calcium level. When vitamin D deficiency is the putative cause of elevated PTH levels, it may take several months for PTH levels to return to normal, even after the vitamin D levels have been normalized. In some patients PTH levels may not return to normal despite high doses of vitamin D. Our data is also consistent with other studies showing that NCHPT is not a benign entity and may be associated with increased risk of osteopenia, osteoporosis and kidney stones which needs to be carefully followed.
  1. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33-39.
  2. Shlapack MA, Rizvi AA. Normocalcemic primary hyperparathyroidism-characteristics and clinical significance of an emerging entity. Am J Med Sci. 2012;343(2):163-6. doi: 10.1097/MAJ.0b013e31823bbb9b.
  3. Šiprová H; Fryšák Z; Souček M. Primary hyperparathyroidism, with a focus on management of the normocalcemic form: To treat or not to treat? Endocr Pract. 2016;22(3):294-301. doi: 10.4158/EP15704.
  4.  Tuna MM, Çalışkan M, Ünal M, Demirci T, Doğan BA, Küçükler K, et al. Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab. 2016;34(3):331-5. doi: 10.1007/s00774-015-0673-3.
  5. Jin J, Mitchell J, Shin J, Berber E, Siperstein AE, Milas M. Calculating an individual maxPTH to aid diagnosis of normocalcemic primary hyperparathyroidism. Surgery. 2012;152(6):1184-92. doi: 10.1016/j.surg.2012.08.013.
  6. Pawlowska M, Cusano NE. An overview of normocalcemic primary hyperparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):413-21. doi: 10.1097/MED.0000000000000198.
  7. Tordjman KM, Greenman Y, Osher E, Shenkerman G, Stern N. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117(11):861-3.
  8. Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: More stone than bone? J Osteoporos 2012;2012:4. doi: 10.1155/2012/128352.
  9. Lundgren E, Rastad J, Thrufjell E, Akerström G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery. 1997;121(3):287-94.
  10. Berger C, Langsetmo L, Hanley D, Adachi J, et al. Relative prevalence of normocalcemic and hypercalcemic hyperparathyroidism in a community-dwelling cohort. Annual Meeting of the American Society of Bone and Mineral Research, San Diego, California. Poster Sessions, Presentation Number: SU0173. 2011.
  11. Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42(3):764-6. doi: 10.1007/s12020-012-9694-z.
  12. Diaz-Soto G, Julian MT, Puiq-Domingo M. Normocalcemic primary hyperparathyroidism: A newly emerging disease needing therapeutic intervention. Hormones (Athens). 2012;11(4):390-6.
  13. Monchik JM, Gorqun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery. 2004;136(6):1242-6.
  14. Lowe H, McMahon DJ, Rubin DR, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Further Characterization of a New Clinical Phenotype. JCEM 2007;92:3001-3005.
  15. Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine. 2012;42(2):419-22.
  16. Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism evidence for a generalized target tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003;88(10):4641-8.
  17. Vignali E, Cetani F, Chiavistelli S, Meola A, Saponaro F, Centoni R, et al. Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Connect. 2015;4(3):172-8. doi: 10.1530/EC-15-003.
  18. Wills MR, Pak CYC, Hammond WG, Bartter FC. Normocalcemic primary hyperparathyroidism. The American Journal of Medicine. 1969;47:384-391.
  19. Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97(1-2):13-9.
  20. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Muenier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporosis Int 2005;16:713-716.
  21. Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of age and serum 25-OH vitamin D on serum parathyroid hormone levels. J Clin Endocrinol Metab. 2012 Nov;97(11):3989-95. doi: 10.1210/jc.2012-2276.
  22. Adami S, Viapiana O, Gatti D, Idolazzi L, Rossini M. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 2008;42(2):267-270.
  23. Peacey SR, Wright D, Harries MJ. Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients. Clin Endocrinol (Oxf) 2004;61:603-606.
  24. Yendt ER, Kovacs KA, Jones G. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: Optimizing calcium and vitamin D intake to levels recommended by expert panels may not be sufficient for correction. Clin Endocrinol (Oxf) 2008;69:855-863.
  25. Clase CM, Norman GL, Beecroft ML, Churchill DN. Albumin-corrected calcium and ionized calcium in stable haemdialysis patients. Nephrol Dial Transplant 2000;15(11):1841-1846.
  26. Boink AB, Buckley BM, Christiansen TF, Covington AK, Maas AH, Müller-Plathe O, Sachs C, Siggaard-Anderson O. Recommendation on sampling, transport, and storage for the determination of the concentration of ionized calcium in whole blood, plasma, and serum. IFC Scientific Division, Working Group on Ion-Selective Electrodes (WGSE). J Int Fed Clin Chem 1992;4:147-52.
  27. Bilezikian JP, Silverberg SJ. Primer on metabolic bone disease and disorders of mineral metabolism. 7th ed. Ed. Clifford Rosen. Washington DC: JW Wiley, 2009.
  28. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism evidence for biphasic disease course. J Clin Endocrinol Metab 1988;67:1294-8.
  29. Udelsman R, Akerstrӧm G, Biagini C, Duh QY, Miccoli P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3595-606.
  30. Monfort M, Delanaye P, Chapelle JP, Cavalier E. Plasma calcium in haemodialysis patients: total calcium or ionized calcium? Should we systematically provide a value of total corrected calcium on our protocols?. Ann Biol Clin (Paris). 2008;66(5):573-6.
Listing : ICMJE   

Creative Commons License Open Access by Symbiosis is licensed under a Creative Commons Attribution 3.0 Unported License